Aktienanalyse zu Immix Biopharma Inc (IMMX)IMMXImmix Biopharma Inc

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immix Biopharma Inc is a good buy right now due to its promising clinical trial results for NXC-201, which showed an 89% complete response rate, and a significant price target increase from analysts, with BofA setting it at $30, indicating over 190% upside potential from the current price of $9.46. However, the stock has experienced a 22.08% decline over the last 20 days, which presents a risk to consider.